What are the causes, diagnostic workup, and treatment options for leukoencephalopathy?

Leukoencephalopathy: Causes, Diagnostic Workup, and Treatment

Leukoencephalopathy encompasses a heterogeneous group of white matter disorders requiring systematic evaluation through advanced neuroimaging and genetic testing, with treatment largely supportive except for specific reversible causes that demand immediate intervention.

Causes

Leukoencephalopathies arise from multiple etiologies that can be broadly categorized:

Genetic/Hereditary Causes

• CSF1R-related leukoencephalopathy: Adult-onset microgliopathy caused by mutations in the CSF1R gene, presenting typically in the fourth or fifth decade with cognitive impairment, behavioral disturbances, and motor dysfunction 1
• AARS-related leukoencephalopathy: Caused by mutations in the alanyl-tRNA synthetase gene 1
• LAMB1-related leukoencephalopathy: Presents with progressive cognitive decline and mood changes in adults 2
• These genetic forms are often fatal and progressive 1

Infectious Causes

• Progressive multifocal leukoencephalopathy (PML): Caused by JC virus reactivation, typically in immunosuppressed patients (HIV, immunosuppressive medications like azathioprine, prednisone) 3
• Viral encephalitides: Including herpes simplex virus, subacute sclerosing panencephalitis 4
• Bacterial and protozoal infections: Including Whipple disease 4

Toxic/Metabolic Causes

• Cocaine-induced toxic leukoencephalopathy: Acute presentation with stroke-like symptoms 5
• Posterior reversible encephalopathy syndrome (PRES): Associated with hypertensive crisis, eclampsia, renal disease, immunosuppressive drugs (cyclosporin, tacrolimus, interferon alfa) 6, 7

Vascular/Microangiopathy

• Leukoencephalopathy with calcifications and cysts: Autosomal recessive cerebral microangiopathy 8

Diagnostic Workup

Neuroimaging Protocol

The diagnostic cornerstone is comprehensive brain MRI with specific sequences, supplemented by CT for calcification detection 1.

MRI Protocol (Primary Recommendation)

• High-spatial-resolution 3D anatomical imaging to visualize white matter lesions and atrophy 1
• Gadolinium-based contrast agent to identify blood-brain-barrier disruption and distinguish inflammatory from degenerative lesions 1
• Diffusion-weighted imaging (DWI): Critical for detecting long-lasting restricted diffusion at the leading edge of white matter lesions—relatively specific for leukoencephalopathies/leukodystrophies versus inflammatory conditions 1
• Susceptibility-weighted imaging (SWI) with preserved phase data to detect parenchymal calcifications 1
• T2-weighted sequences: Show hyperintensity in affected white matter regions 6

CT Protocol (Complementary)

• Thin slices ≤1mm with multiplanar reconstructions in all three planes 1
• Superior for detecting small white matter calcifications, especially if SWI unavailable 1

Key Imaging Findings by Etiology

CSF1R-related leukoencephalopathy 1:

• Frontoparietal white matter lesions (most common)
• Callosal thinning
• Foci of restricted diffusion (long-lasting—a distinguishing feature)
• White matter calcifications on CT (hallmark finding—spotty, stepping-stone, or serpiginous pattern)
• Progressive brain atrophy, predominantly frontoparietal

PRES 6, 7:

• Diffuse T2 hyperintensity selectively involving parieto-occipital white matter
• May involve grey matter occasionally
• Edematous lesions can spread to basal ganglia, brainstem, cerebellum

PML 3:

• Confluent white matter lesions throughout brain
• Asymmetric distribution common

Genetic Testing

• Whole-exome sequencing for suspected hereditary forms when imaging suggests genetic etiology 2
• CSF1R gene mutation analysis when imaging shows characteristic frontoparietal white matter disease with calcifications 1

Cerebrospinal Fluid Analysis

• JC virus DNA PCR for suspected PML 3
• Cell count, protein, glucose for infectious workup 4

Laboratory Workup

• Blood pressure monitoring (hypertensive crisis in PRES) 6, 7
• Toxicology screen (cocaine, other substances) 5
• HIV testing and CD4 count 3
• Metabolic panel to exclude metabolic causes 2
• Review medication history (immunosuppressants, chemotherapy) 6, 3

Nuclear Medicine (Adjunctive)

• FDG-PET: Shows glucose hypometabolism in cerebral lobes, especially frontal lobes in CSF1R-related disease 1
• SPECT: Hypometabolism in frontal and parietal lobes 1
• Not routinely recommended but may provide supportive data 1

Treatment Options

Reversible Causes (Immediate Intervention Required)

PRES 6:

• Gradual blood pressure lowering (avoid sudden hypoperfusion)
• Withdrawal of offending immunosuppressive agents
• Seizure prevention and management
• Early recognition critical—prompt treatment causes syndrome reversal; delay results in permanent brain damage

Cocaine-induced toxic leukoencephalopathy 5:

• Supportive care (primary approach)
• Other reported modalities: steroids, plasma exchange, intravenous immunoglobulin (limited evidence)
• Substance abuse counseling

PML 3:

• Withdrawal of immunosuppressive medications (only established intervention for non-HIV patients)
• Maintain minimally effective immunosuppression dose to reduce risk
• No specific antiviral therapy available
• High mortality rate

Genetic/Progressive Forms

CSF1R-related leukoencephalopathy 1, 9:

• No disease-modifying therapies currently available
• Supportive care and symptomatic management
• Progressive and fatal course
• Clinical trials needed for therapeutic development

Leukoencephalopathy with calcifications and cysts 8:

• Bevacizumab (anti-VEGF antibody): Case report showed improvement in bradykinesia, range of motion, and reduction in cyst volume and white matter lesions after biweekly infusions for >1 year
• Requires further cohort studies to establish efficacy

Hereditary leukoencephalopathies 10:

• Hematopoietic stem cell transplantation offers promise for select diseases
• Early diagnosis critical for optimal management

Infectious Causes

• Herpes simplex encephalitis: Effective treatment if suspected and treated early 4
• Pathogen-specific antimicrobial therapy based on identified organism

Critical Diagnostic Pitfalls

Common mimics of CSF1R-related leukoencephalopathy include multiple sclerosis, cerebral vasculitis, and CADASIL 1. The key distinguishing features are:

• White matter calcifications (not typical in MS or vasculitis) 1
• Long-lasting restricted diffusion on DWI (specific for leukoencephalopathies) 1
• Mean diagnostic delay is 2.3 years from symptom onset 1

For PML, comorbid conditions causing encephalopathy (hepatic encephalopathy, infections) can delay diagnosis 3. Maintain high suspicion in immunosuppressed patients with progressive neurological decline.

Women with CSF1R mutations have statistically significant earlier age of onset (40 vs 43 years, p=0.041) 1.